Success Metrics

Clinical Success Rate

75.0%

Based on 3 completed trials

Completion Rate

75%(3/4)

Active Trials

1(20%)

Results Posted

33%(1 trials)

Terminated

1(20%)

Phase Distribution

Ph early_phase_1

40%

Ph phase_2

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Early Phase 1First-in-human

2(66.7%)

Phase 2Efficacy & side effects

1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Terminated(1)

Detailed Status

Completed3

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

75.0%

Most Advanced

Phase 2

Trials by Phase

Early Phase 12 (66.7%)

Phase 21 (33.3%)

Trials by Status

completed360%

terminated120%

active_not_recruiting120%

Recent Activity

1 active trials

Showing 5 of 5

active_not_recruiting

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

NCT03236311

completedearly_phase_1

An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients

NCT02669563

Clinical Trials (5)

Showing 5 of 5 trials

NCT03648905

Clinical Laboratory Evaluation of Chronic Autonomic Failure

Active Not Recruiting

NCT05625490Early Phase 1

Myocardial Perfusion Imaging Galmydar Rest/Stress

Completed

NCT00775853

Biomarkers of Risk of Parkinson Disease

Completed

NCT03236311Phase 2

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Terminated

NCT02669563Early Phase 1

An Exploratory Study of 18F-Labeled Hydroxyphenethylguanidines in Heart Failure Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 5